Principle Wealth Partners LLC Buys 10,087 Shares of Organon & Co. (NYSE:OGN)

Principle Wealth Partners LLC increased its stake in shares of Organon & Co. (NYSE:OGN) by 88.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 21,459 shares of the company’s stock after buying an additional 10,087 shares during the period. Principle Wealth Partners LLC’s holdings in Organon & Co. were worth $309,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of OGN. AE Wealth Management LLC bought a new stake in shares of Organon & Co. during the 3rd quarter worth about $305,000. Exchange Traded Concepts LLC bought a new stake in shares of Organon & Co. during the 3rd quarter worth about $165,000. Czech National Bank boosted its holdings in shares of Organon & Co. by 47.9% during the 3rd quarter. Czech National Bank now owns 44,668 shares of the company’s stock worth $775,000 after buying an additional 14,474 shares during the period. Denali Advisors LLC boosted its holdings in shares of Organon & Co. by 279.4% during the 3rd quarter. Denali Advisors LLC now owns 7,247 shares of the company’s stock worth $126,000 after buying an additional 5,337 shares during the period. Finally, Bfsg LLC bought a new stake in shares of Organon & Co. during the 3rd quarter worth about $180,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Up 0.7 %

NYSE OGN opened at $18.55 on Monday. The company has a market capitalization of $4.77 billion, a P/E ratio of 4.64, a P/E/G ratio of 0.88 and a beta of 0.82. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.79. The firm has a 50-day moving average price of $18.14 and a two-hundred day moving average price of $15.68.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.14. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. Equities analysts expect that Organon & Co. will post 4.08 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Investors of record on Monday, February 26th were given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 6.04%. The ex-dividend date of this dividend was Friday, February 23rd. Organon & Co.’s dividend payout ratio is 28.00%.

Insider Buying and Selling

In other Organon & Co. news, insider Kirke Weaver bought 2,720 shares of Organon & Co. stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $18.36 per share, with a total value of $49,939.20. Following the acquisition, the insider now directly owns 15,181 shares of the company’s stock, valued at approximately $278,723.16. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.17% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, The Goldman Sachs Group lifted their target price on shares of Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, February 20th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.